Prostate Adenocarcinoma

About
Mappings

OncoTree: Prostate Adenocarcinoma (oncotree:PRAD)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone FDA
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone FDA
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Niraparib, Prednisone FDA
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) ATM pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) ATM oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BARD1 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BARD1 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BRIP1 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BRIP1 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) CDK12 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) CDK12 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) CHEK1 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) CHEK1 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) CHEK2 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) CHEK2 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) FANCL pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) FANCL oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) PALB2 pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) PALB2 oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) RAD51B pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) RAD51B oncogenic variants Prostate Adenocarcinoma Talazoparib FDA
Sensitivity (+) RAD51C pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) RAD51C oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) RAD51D pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) RAD51D oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) RAD54L pathogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) RAD54L oncogenic variants Prostate Adenocarcinoma Olaparib FDA
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone FDA
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone FDA
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone FDA
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone FDA
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone FDA
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone FDA
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Rucaparib FDA
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Rucaparib FDA
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Rucaparib FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Rucaparib FDA
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) ATM pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) ATM oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) ATR oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) CDK12 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) ATR pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) FANCA oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) CHEK2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) CHEK2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) FANCA pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) MLH1 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) PALB2 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) PALB2 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) MLH1 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) MRE11 oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) RAD51C pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) RAD51C oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) MRE11 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) NBN oncogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) NBN pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) CDK12 pathogenic variants Prostate Adenocarcinoma Enzalutamide, Talazoparib FDA
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Olaparib HC
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Olaparib HC
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Olaparib HC
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Olaparib HC
Sensitivity (+) ATM pathogenic variants Prostate Adenocarcinoma Olaparib HC
Sensitivity (+) ATM oncogenic variants Prostate Adenocarcinoma Olaparib HC
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone HC
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone HC
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone HC
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisolone HC
Sensitivity (+) BRCA1 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone HC
Sensitivity (+) BRCA1 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone HC
Sensitivity (+) BRCA2 oncogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone HC
Sensitivity (+) BRCA2 pathogenic variants Prostate Adenocarcinoma Abiraterone acetate, Olaparib, Prednisone HC